News Summary: Amgen Q4 net jumps on higher sales

Published



THE BOTTOM LINE: A tax benefit, an acquisition and price hikes that boosted drug revenue helped Amgen, the world’s biggest maker of biologic drugs, increase fourth-quarter profit by 30 percent.

THE NUMBERS: Net income was $1.02 billion, while adjusted profit was $1.39 billion, or $1.82 per share — 13 cents more than analysts expected. Revenue totaled $5.01 billion, up 13 percent.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.